Demographic and Clinical Characteristics of the Study Population, Stratified by Final Influenza Vaccine (V) and Statin (S) Exposure Status per Influenza Season
| Characteristic . | V+/S+ (n = 39 342) . | V+/S− (n = 66 532) . | V−/S+ (n = 52 685) . | V−/S− (n = 289 029) . |
|---|---|---|---|---|
| Sexa | ||||
| Female | 20 988 (53.4) | 40 761 (61.3) | 26 045 (49.4) | 155 967 (54.0) |
| Male | 18 354 (46.7) | 25 771 (38.7) | 26 640 (50.6) | 133 062 (46.0) |
| Age, ya | ||||
| 45–54 | 8414 (21.4) | 26 325 (39.6) | 21 119 (40.1) | 186 006 (64.4) |
| 55–64 | 14 946 (38.0) | 22 386 (33.7) | 21 204 (40.3) | 79 516 (27.5) |
| ≥65 | 15 982 (40.6) | 17 821 (26.8) | 10 362 (19.7) | 23 507 (8.1) |
| Diagnosis | ||||
| COPDa | ||||
| Yes | 11 827 (30.1) | 17 162 (25.8) | 11 721 (22.3) | 44 180 (15.3) |
| No | 27 515 (69.9) | 49 370 (74.2) | 40 964 (77.8) | 244 849 (84.7) |
| CVDa | ||||
| Yes | 16 803 (42.7) | 13 482 (20.3) | 17 866 (33.9) | 32 837 (11.4) |
| No | 22 539 (57.3) | 53 050 (79.7) | 34 819 (66.1) | 256 192 (88.6) |
| Circulatory diseasea | ||||
| Yes | 31 537 (80.2) | 33 852 (50.9) | 39 373 (74.7) | 106 595 (36.9) |
| No | 7805 (19.8) | 32 680 (49.1) | 13 312 (25.3) | 182 434 (63.1) |
| Diabetesa | ||||
| Yes | 18 133 (46.1) | 8843 (13.3) | 19 493 (37.0) | 21 810 (7.6) |
| No | 21 209 (53.9) | 57 689 (86.7) | 33 192 (63.0) | 267 219 (92.5) |
| Received PPSV23a | ||||
| Yes | 19 071 (48.5) | 15 925 (23.9) | 11 215 (21.3) | 13 218 (4.6) |
| No | 20 271 (51.5) | 50 607 (76.1) | 41 470 (78.7) | 275 811 (95.4) |
| Well-care visits in influenza season, no.a | ||||
| 0 | 14 250 (36.2) | 23 676 (35.6) | 38 028 (72.2) | 228 883 (79.2) |
| ≥1 | 25 092 (63.8) | 42 856 (64.4) | 14 657 (27.8) | 60 146 (20.8) |
| Characteristic . | V+/S+ (n = 39 342) . | V+/S− (n = 66 532) . | V−/S+ (n = 52 685) . | V−/S− (n = 289 029) . |
|---|---|---|---|---|
| Sexa | ||||
| Female | 20 988 (53.4) | 40 761 (61.3) | 26 045 (49.4) | 155 967 (54.0) |
| Male | 18 354 (46.7) | 25 771 (38.7) | 26 640 (50.6) | 133 062 (46.0) |
| Age, ya | ||||
| 45–54 | 8414 (21.4) | 26 325 (39.6) | 21 119 (40.1) | 186 006 (64.4) |
| 55–64 | 14 946 (38.0) | 22 386 (33.7) | 21 204 (40.3) | 79 516 (27.5) |
| ≥65 | 15 982 (40.6) | 17 821 (26.8) | 10 362 (19.7) | 23 507 (8.1) |
| Diagnosis | ||||
| COPDa | ||||
| Yes | 11 827 (30.1) | 17 162 (25.8) | 11 721 (22.3) | 44 180 (15.3) |
| No | 27 515 (69.9) | 49 370 (74.2) | 40 964 (77.8) | 244 849 (84.7) |
| CVDa | ||||
| Yes | 16 803 (42.7) | 13 482 (20.3) | 17 866 (33.9) | 32 837 (11.4) |
| No | 22 539 (57.3) | 53 050 (79.7) | 34 819 (66.1) | 256 192 (88.6) |
| Circulatory diseasea | ||||
| Yes | 31 537 (80.2) | 33 852 (50.9) | 39 373 (74.7) | 106 595 (36.9) |
| No | 7805 (19.8) | 32 680 (49.1) | 13 312 (25.3) | 182 434 (63.1) |
| Diabetesa | ||||
| Yes | 18 133 (46.1) | 8843 (13.3) | 19 493 (37.0) | 21 810 (7.6) |
| No | 21 209 (53.9) | 57 689 (86.7) | 33 192 (63.0) | 267 219 (92.5) |
| Received PPSV23a | ||||
| Yes | 19 071 (48.5) | 15 925 (23.9) | 11 215 (21.3) | 13 218 (4.6) |
| No | 20 271 (51.5) | 50 607 (76.1) | 41 470 (78.7) | 275 811 (95.4) |
| Well-care visits in influenza season, no.a | ||||
| 0 | 14 250 (36.2) | 23 676 (35.6) | 38 028 (72.2) | 228 883 (79.2) |
| ≥1 | 25 092 (63.8) | 42 856 (64.4) | 14 657 (27.8) | 60 146 (20.8) |
Data are no. (%) of person-seasons.
Abbreviations: COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; PPSV23, 23-valent pneumococcal polysaccharide vaccine; −, nonuse; +, use.
aP < .0001, by χ2 analysis.
Demographic and Clinical Characteristics of the Study Population, Stratified by Final Influenza Vaccine (V) and Statin (S) Exposure Status per Influenza Season
| Characteristic . | V+/S+ (n = 39 342) . | V+/S− (n = 66 532) . | V−/S+ (n = 52 685) . | V−/S− (n = 289 029) . |
|---|---|---|---|---|
| Sexa | ||||
| Female | 20 988 (53.4) | 40 761 (61.3) | 26 045 (49.4) | 155 967 (54.0) |
| Male | 18 354 (46.7) | 25 771 (38.7) | 26 640 (50.6) | 133 062 (46.0) |
| Age, ya | ||||
| 45–54 | 8414 (21.4) | 26 325 (39.6) | 21 119 (40.1) | 186 006 (64.4) |
| 55–64 | 14 946 (38.0) | 22 386 (33.7) | 21 204 (40.3) | 79 516 (27.5) |
| ≥65 | 15 982 (40.6) | 17 821 (26.8) | 10 362 (19.7) | 23 507 (8.1) |
| Diagnosis | ||||
| COPDa | ||||
| Yes | 11 827 (30.1) | 17 162 (25.8) | 11 721 (22.3) | 44 180 (15.3) |
| No | 27 515 (69.9) | 49 370 (74.2) | 40 964 (77.8) | 244 849 (84.7) |
| CVDa | ||||
| Yes | 16 803 (42.7) | 13 482 (20.3) | 17 866 (33.9) | 32 837 (11.4) |
| No | 22 539 (57.3) | 53 050 (79.7) | 34 819 (66.1) | 256 192 (88.6) |
| Circulatory diseasea | ||||
| Yes | 31 537 (80.2) | 33 852 (50.9) | 39 373 (74.7) | 106 595 (36.9) |
| No | 7805 (19.8) | 32 680 (49.1) | 13 312 (25.3) | 182 434 (63.1) |
| Diabetesa | ||||
| Yes | 18 133 (46.1) | 8843 (13.3) | 19 493 (37.0) | 21 810 (7.6) |
| No | 21 209 (53.9) | 57 689 (86.7) | 33 192 (63.0) | 267 219 (92.5) |
| Received PPSV23a | ||||
| Yes | 19 071 (48.5) | 15 925 (23.9) | 11 215 (21.3) | 13 218 (4.6) |
| No | 20 271 (51.5) | 50 607 (76.1) | 41 470 (78.7) | 275 811 (95.4) |
| Well-care visits in influenza season, no.a | ||||
| 0 | 14 250 (36.2) | 23 676 (35.6) | 38 028 (72.2) | 228 883 (79.2) |
| ≥1 | 25 092 (63.8) | 42 856 (64.4) | 14 657 (27.8) | 60 146 (20.8) |
| Characteristic . | V+/S+ (n = 39 342) . | V+/S− (n = 66 532) . | V−/S+ (n = 52 685) . | V−/S− (n = 289 029) . |
|---|---|---|---|---|
| Sexa | ||||
| Female | 20 988 (53.4) | 40 761 (61.3) | 26 045 (49.4) | 155 967 (54.0) |
| Male | 18 354 (46.7) | 25 771 (38.7) | 26 640 (50.6) | 133 062 (46.0) |
| Age, ya | ||||
| 45–54 | 8414 (21.4) | 26 325 (39.6) | 21 119 (40.1) | 186 006 (64.4) |
| 55–64 | 14 946 (38.0) | 22 386 (33.7) | 21 204 (40.3) | 79 516 (27.5) |
| ≥65 | 15 982 (40.6) | 17 821 (26.8) | 10 362 (19.7) | 23 507 (8.1) |
| Diagnosis | ||||
| COPDa | ||||
| Yes | 11 827 (30.1) | 17 162 (25.8) | 11 721 (22.3) | 44 180 (15.3) |
| No | 27 515 (69.9) | 49 370 (74.2) | 40 964 (77.8) | 244 849 (84.7) |
| CVDa | ||||
| Yes | 16 803 (42.7) | 13 482 (20.3) | 17 866 (33.9) | 32 837 (11.4) |
| No | 22 539 (57.3) | 53 050 (79.7) | 34 819 (66.1) | 256 192 (88.6) |
| Circulatory diseasea | ||||
| Yes | 31 537 (80.2) | 33 852 (50.9) | 39 373 (74.7) | 106 595 (36.9) |
| No | 7805 (19.8) | 32 680 (49.1) | 13 312 (25.3) | 182 434 (63.1) |
| Diabetesa | ||||
| Yes | 18 133 (46.1) | 8843 (13.3) | 19 493 (37.0) | 21 810 (7.6) |
| No | 21 209 (53.9) | 57 689 (86.7) | 33 192 (63.0) | 267 219 (92.5) |
| Received PPSV23a | ||||
| Yes | 19 071 (48.5) | 15 925 (23.9) | 11 215 (21.3) | 13 218 (4.6) |
| No | 20 271 (51.5) | 50 607 (76.1) | 41 470 (78.7) | 275 811 (95.4) |
| Well-care visits in influenza season, no.a | ||||
| 0 | 14 250 (36.2) | 23 676 (35.6) | 38 028 (72.2) | 228 883 (79.2) |
| ≥1 | 25 092 (63.8) | 42 856 (64.4) | 14 657 (27.8) | 60 146 (20.8) |
Data are no. (%) of person-seasons.
Abbreviations: COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; PPSV23, 23-valent pneumococcal polysaccharide vaccine; −, nonuse; +, use.
aP < .0001, by χ2 analysis.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
